Shares of Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN – Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.11 and traded as high as $0.16. Enzon Pharmaceuticals shares last traded at $0.16, with a volume of 47,000 shares trading hands.
Enzon Pharmaceuticals Stock Performance
The firm has a market cap of $12.44 million, a P/E ratio of 16.76 and a beta of 0.52. The stock’s 50 day simple moving average is $0.16 and its 200 day simple moving average is $0.11.
Enzon Pharmaceuticals Company Profile
Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
Featured Stories
- Five stocks we like better than Enzon Pharmaceuticals
- Dividend Capture Strategy: What You Need to Know
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What is Forex and How Does it Work?
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Trading Halts Explained
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
